Quantcast

Latest Juvenile idiopathic arthritis Stories

2009-06-11 09:24:31

Elevated levels of the inflammatory biomarkers Myeloid Related Protein (MRP*) 8/14 predict an increased risk of relapse following withdrawal of methotrexate (MTX) therapy in children with juvenile idiopathic arthritis (JIA) who have achieved inactive disease status, according to a new study presented today presented today at PReS 2009, a joint congress with the 2009 Congress of the European League Against Rheumatism (EULAR) in Copenhagen, Denmark.

2009-06-09 17:01:00

- Additional data reinforce long-term efficacy of ACTEMRA across a broad range of rheumatoid arthritis patient populations - NUTLEY, N.J., June 9 /PRNewswire/ -- One-year data from the two-year Phase III LITHE (TociLIzumab Safety and THE Prevention of Structural Joint Damage) study demonstrated that a greater proportion of rheumatoid arthritis (RA) patients treated with ACTEMRA(R) (tocilizumab), a novel interleukin-6 (IL-6) receptor inhibitor, in combination with methotrexate, experienced a...

2009-06-04 07:00:00

- Results of Phase III clinical studies highlight benefits of ACTEMRA as a treatment for rheumatoid arthritis - NUTLEY, N.J., June 4 /PRNewswire/ -- Roche today announced that oral and poster presentations highlighting results from the extensive multi-national ACTEMRA(R) (tocilizumab) clinical development program will be presented at the 10th Annual Congress of the European League Against Rheumatism (EULAR), which will take place June 10-13, 2009, in Copenhagen, Denmark.

2009-06-02 00:58:08

Patients suffered fewer rheumatoid arthritis symptoms when their gum disease was treated, U.S.

2009-05-25 00:00:00

- Fifth International Phase III ACTEMRA Study Meets its Primary Endpoints - NUTLEY, N.J., May 25 /PRNewswire/ -- Roche today announced that two-year data from the LITHE (TociLIzumab Safety and THE Prevention of Structural Joint Damage) study demonstrated that ACTEMRA(R) (tocilizumab) continued to inhibit the progression of structural damage to joints in patients with rheumatoid arthritis (RA).

2009-03-26 08:20:00

Twenty Percent of Surveyed MCO Pharmacy Directors Say They Will Alter Reimbursement of TNF-alpha Inhibitors for Juvenile Idiopathic Arthritis and Pediatric Crohn's Disease, According to a New Report from Decision Resources WALTHAM, Mass., March 26 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that 30 percent of surveyed rheumatologists have altered their prescription patterns for juvenile idiopathic...

2009-02-26 17:01:50

Arthritis, common among those having heart disease, may be a barrier for patients to getting needed physical activity, a U.S.

2008-12-04 00:30:00

NUTLEY, N.J., Dec. 4 /PRNewswire/ -- Roche today announced that the U.S.

2008-10-28 00:00:08

Bristol-Myers Squibb Company (NYSE: BMY) today announced at the American College of Rheumatology (ACR) Annual Scientific Meeting in San Francisco results from a 10-month study which showed that ORENCIA(R) (abatacept), compared to placebo, significantly improved multiple aspects of health-related quality of life (HRQoL): physical and psychosocial well being, pain and sleep quality in juvenile idiopathic arthritis (JIA) patients between the ages 6 and 17 years.

2008-10-25 21:00:11

NUTLEY, N.J., Oct. 25 /PRNewswire/ -- One-year data from a two-year Phase III study demonstrated that ACTEMRA(R) (tocilizumab) significantly inhibited the progression of structural joint damage in patients with rheumatoid arthritis (RA).


Word of the Day
swell-mobsman
  • A member of the swell-mob; a genteelly clad pickpocket. Sometimes mobsman.
Use of the word 'swell-mobsman' dates at least to the early 1800s.